Hartwig to adopt Ultima Genomics’ UG200 sequencing system to accelerate implementation of whole-genome-based clinical genomics workflows on Solaris 2.0 technology Hartwig and Ultima to continue implementation and validation of ppmSeq, the only decentralizable whole-genome solution commercially available today for monitoring of minimal residual disease (MRD) with low single-digit part-per-million sensitivity AMSTERDAM and FREMONT, Calif. — […]

Updated kits deliver improved sensitivity and receptor recovery for single cell immune repertoire profiling at unprecedented scale SEATTLE — Parse Biosciences, the leading provider of scalable and accessible single cell sequencing solutions, today launched the next generation of its Evercode™ TCR and Evercode™ BCR kits, shipping to customers worldwide. The updated kits deliver a streamlined workflow, better whole transcriptome […]

CellVoyant and Axol Bioscience announce strategic collaboration to advance AI-guided predictive imaging assays for cardiomyocyte manufacturing Collaboration combines CellVoyant AI-powered FateView™ platform with Axol Bioscience induced pluripotent stem cell (iPSC) expertise to enable predictive, non-destructive assessment of cardiomyocyte differentiation processes, enabling the generation of highly pure cell populations at scale. BRISTOL, UK and EDINBURGH, UK […]

Partnership provides Human Cell Atlas members with access to the Tapestri Platform for integrated single-cell DNA, RNA, and protein analysis SAN FRANCISCO — Mission Bio, the leader in single-cell multiomics solutions, today announced a collaboration with the Human Cell Atlas (HCA), a global consortium working to create comprehensive reference maps of all human cells to advance the […]

StrataMap Spatial gives researchers access to spatial biology at true single cell resolution for discovery without boundaries Whole-transcriptome profiling across a large tissue capture area can generate 2x more unique genes per sample than probe-based technologies SAN DIEGO — Illumina, Inc. (NASDAQ: ILMN) today announced the launch of the StrataMap Spatial Solution, offering an unmatched breadth […]

Alithea Genomics, a pioneering biotech company specializing in scalable RNA sequencing solutions, today announced a new agreement with Revvity Inc. to broaden access to MERCURIUS™ DRUG-seq and MERCURIUS™ Total DRUG-seq solutions through Revvity’s global commercial network.  The collaboration brings together Alithea Genomics’ scalable high-throughput transcriptomics technologies with Revvity’s comprehensive drug discovery and screening portfolio, enabling […]

Company plans to showcase new volumetric MERFISH datasets in mouse brain and human neurodegenerative brain tissue, generated on the existing MERSCOPE Ultra™ Platform WALTHAM, Mass. — Vizgen, Inc., a leader in spatial multiomics and developer of the MERSCOPE Ultra™ Platform, today announced it will debut a 3D Volumetric Tissue Mapping dataset in neurodegenerative brain tissue […]

StrataMap Spatial gives researchers access to spatial biology at true single cell resolution for discovery without boundaries Whole-transcriptome profiling across a large tissue capture area can generate 2x more unique genes per sample than probe-based technologies SAN DIEGO — Illumina, Inc. (NASDAQ: ILMN) today announced the launch of the StrataMap Spatial Solution, offering an unmatched breadth […]

MilliporeSigma appoints Clara Sattler de Sousa e Brito and Robert Machinek to strengthen leadership team. Clara Sattler de Sousa e Brito appointed Head of Discovery Solutions, bringing extensive international leadership experience across healthcare, medtech and the chemical industry Robert Machinek appointed Head of Strategy & Business Development, bringing deep expertise in life science strategy, M&A […]

Combined company to operate as Treeline Biosciences, advancing a deep pipeline of small molecule inhibitors, protein degraders and targeted therapy antibody-drug conjugates Company to be led by Treeline CEO and co-founder Josh Bilenker, MD, and experienced team of proven drug developers Treeline’s pipeline includes three Phase 1 programs with multiple anticipated clinical data readouts beginning in 2027 Well capitalized with over $900 million in cash expected […]